Quarterly Result31 Jul 2025, 06:02 pm
Mankind Pharma Reports 24.5% Revenue Growth in Q1FY26 with EBITDA Margin at 23.8%
AI Summary
Mankind Pharma, one of India's largest pharmaceutical companies, has announced its financial results for the first quarter ended 30th June 2025. The company's revenue grew by 24.5% YoY, with EBITDA margins at 23.8%. The growth was led by continued outperformance in the Chronic segment, strong growth in the Consumer segment, and BSV consolidation. The company also reported visible encouraging trends with 1.8x volume growth to IPM, led by outperformance in Anti-infectives & Respiratory segment, among others.
Key Highlights
- Revenue from Operations at INR 3,570 Cr, up by 24.5% YoY
- EBITDA margin of 23.8% up by 20 bps YoY
- Domestic revenue at INR 3,101 Cr, up 18.9% YoY
- Strong revenue growth in Consumer Healthcare Business
- Revenue growth of 81.1% YoY in Exports primarily due to consolidation of BSV